PharMAHTA

PharMAHTA s.r.o. is a consulting firm focused on market access and health technology assessment (HTA) in the Czech Republic and Slovakia. Its services cover reimbursement strategy, HTA documentation for SÚKL administrative proceedings, pharmacoeconomic analyses, negotiations with payers, and long-term market access support for product portfolios. It also works on medical devices, performance-based reimbursement schemes, and specific areas such as oncology, vaccines, rare diseases and VILP.

The clients are pharmaceutical and medical device companies bringing innovative medicines and devices into the reimbursement system. The website describes the work as project-based consulting; no pricing or revenue model details are published.

The company is registered in Prague (Praha 1) and was founded in 2025 according to the registry. Its team is led by Martin Ševec (Founder, Managing Partner), with Aneta Schimmerová and Robert Chlád listed as Managing Partners and HEOR Managers. From July 2026 it cooperates with Sprinx Pharma and CEEOR on the Market Access Zpravodaj newsletter.

Product: Market access and HTA consulting: reimbursement strategy, SÚKL HTA dossiers, pharmacoeconomic models and payer negotiation support.